Metagenomi’s (MGX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Metagenomi (NASDAQ:MGX) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $7.00 price target on the stock.

A number of other analysts have also recently commented on the company. Chardan Capital reiterated a “buy” rating and set a $15.00 target price on shares of Metagenomi in a research report on Wednesday, November 20th. BMO Capital Markets cut their price target on Metagenomi from $22.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, August 15th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Metagenomi Stock Performance

Metagenomi stock opened at $1.89 on Thursday. The stock’s fifty day moving average is $2.06 and its two-hundred day moving average is $3.69. Metagenomi has a 1-year low of $1.61 and a 1-year high of $12.74.

Institutional Trading of Metagenomi

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. acquired a new stake in shares of Metagenomi in the first quarter valued at approximately $1,894,000. Artal Group S.A. acquired a new stake in Metagenomi during the 1st quarter valued at $3,165,000. RA Capital Management L.P. purchased a new position in Metagenomi during the first quarter worth $18,404,000. Farallon Capital Management LLC acquired a new position in shares of Metagenomi in the first quarter worth $14,171,000. Finally, Rhumbline Advisers purchased a new stake in shares of Metagenomi in the second quarter valued at $26,000.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.